相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review
Ivan Urits et al.
CURRENT PAIN AND HEADACHE REPORTS (2019)
Psychometric Validation of the Role Function Restrictive Domain of the Migraine Specific Quality-of-Life Questionnaire Version 2.1 Electronic Patient-Reported Outcome in Patients With Episodic and Chronic Migraine
Rebecca M. Speck et al.
HEADACHE (2019)
Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
Peter J. Goadsby et al.
CEPHALALGIA (2019)
Gepants for the treatment of migraine
Andrea Negro et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class
Richard Hargreaves et al.
HEADACHE (2019)
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention (vol 20, 6, 2019)
Simona Sacco et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Erenumab in chronic migraine Patient-reported outcomes in a randomized double-blind study
Richard B. Lipton et al.
NEUROLOGY (2019)
Erenumab in chronic migraine with medication overuse Subgroup analysis of a randomized trial
Stewart J. Tepper et al.
NEUROLOGY (2019)
Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
Bianca Raffaelli et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Does inflammation have a role in migraine?
Lars Edvinsson et al.
NATURE REVIEWS NEUROLOGY (2019)
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
Simona Sacco et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
Messoud Ashina et al.
CEPHALALGIA (2018)
A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
Orit Cohen-Barak et al.
CEPHALALGIA (2018)
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
David W. Dodick et al.
CEPHALALGIA (2018)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina
Christophe Depre et al.
HEADACHE (2018)
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine A Randomized Clinical Trial
David W. Dodick et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
CGRP as the target of new migraine therapies - successful translation from bench to clinic
Lars Edvinsson et al.
NATURE REVIEWS NEUROLOGY (2018)
Evaluation of Galcanezumab for the Prevention of Episodic Migraine The EVOLVE-1 Randomized Clinical Trial
Virginia L. Stauffer et al.
JAMA NEUROLOGY (2018)
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention A Randomized Clinical Trial
Vladimir Skljarevski et al.
JAMA NEUROLOGY (2018)
Estimating, the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective
Richard B. Lipton et al.
JOURNAL OF MEDICAL ECONOMICS (2018)
History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment
Stewart J. Tepper
HEADACHE (2018)
A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
Angelo Camporeale et al.
BMC NEUROLOGY (2018)
Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018
Stewart J. Tepper
HEADACHE (2018)
Early onset of efficacy with erenumab in patients with episodic and chronic migraine
Todd Schwedt et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
Uwe Reuter et al.
LANCET (2018)
Galcanezumab in chronic migraine The randomized, double-blind, placebo-controlled REGAIN study
Holland C. Detke et al.
NEUROLOGY (2018)
Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine
Jan de Hoon et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Stewart Tepper et al.
LANCET NEUROLOGY (2017)
Human models of migraine - short-term pain for long-term gain
Messoud Ashina et al.
NATURE REVIEWS NEUROLOGY (2017)
Anti-CGRP antibodies block CGRP-induced diarrhea in mice
Eric A. Kaiser et al.
NEUROPEPTIDES (2017)
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Controlled Trial of Erenumab for Episodic Migraine
Peter J. Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects
Thuy Vu et al.
PHARMACEUTICAL RESEARCH (2017)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
David Monteith et al.
FRONTIERS IN PHARMACOLOGY (2017)
Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
Lanfranco Pellesi et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine
Cesar Ramon et al.
CURRENT OPINION IN NEUROLOGY (2017)
Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015
Theo Vos et al.
LANCET (2016)
Wiping Out CGRP: Potential Cardiovascular Risks
Antoinette MaassenVanDenBrink et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor
Licheng Shi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
TEV-48125: a Review of a Monoclonal CGRP Antibody in Development for the Preventive Treatment of Migraine
Sarah Walter et al.
CURRENT PAIN AND HEADACHE REPORTS (2015)
Pharmacological Trials in Migraine: It's Time to Reappraise Where the Headache Is and What the Pain Is Like
Piero Barbanti et al.
HEADACHE (2015)
Monoclonal Antibodies for Migraine: Preventing Calcitonin Gene-Related Peptide Activity
Marcelo E. Bigal et al.
CNS DRUGS (2014)
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
David W. Dodick et al.
LANCET NEUROLOGY (2014)
Calcitonin Gene-Related Peptide (CGRP) and Migraine Current Understanding and State of Development
Marcelo E. Bigal et al.
HEADACHE (2013)
Validating Migraine-Specific Quality of Life Questionnaire v2.1 in Episodic and Chronic Migraine
Christine L. Bagley et al.
HEADACHE (2012)
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine
R. B. Lipton et al.
NEUROLOGY (2011)
CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat
J. Zeller et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Epidemiology and comorbidity of headache
Rigmor Jensen et al.
LANCET NEUROLOGY (2008)
Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine
J Olesen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Vascular actions of calcitonin gene-related peptide and adrenomedullin
SD Brain et al.
PHYSIOLOGICAL REVIEWS (2004)
CGRP may play a causative role in migraine
LH Lassen et al.
CEPHALALGIA (2002)
Neurotransmitter coding of enteric neurones in the submucous plexus is changed in non-inflamed rectum of patients with Crohn's disease
J Schneider et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2001)
Migraine and beyond: cardiovascular therapeutic potential for CGRP modulators
SA Doggrell
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2001)
Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache - Therapeutic implications
L Edvinsson
CNS DRUGS (2001)
Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist
H Doods et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
分享论文
